Growth hormone treatment adjusted for growth hormone sensitivity in idiopathic short stature
Authors' conclusion
Children with ISS, decreased IGF-1 levels, and a normal stimulated GH peak show a good response to rhGH treatment. The IGFGT is a useful tool for selecting this subgroup from ISS patients and optimizing rhGH dose.
Study context
- Population
- Children with idiopathic short stature (ISS) (height < −2.5 standard deviation score (SDS)), IGF-1 < −2.0 SDS on 2 occasions and peak growth hormone (GH) >10 µg/L58 reached near-adult height (NAH)
- Participants
- 129 children
- Exposure
- Recombinant human growth hormone (rhGH) dose adjusted for GH sensitivity
- Outcome
- Long-term growth response to rhGH
Main finding
As reported in the abstract
Height at near-adult height (NAH)
Average height at NAH (SDS)
−1.0 ± 1.0 SDS
Gain vs height at start
2.1 ± 0.8 SDS
Above predicted adult height (PAH) at start
1.5 ± 0.8 SDS
Below target height
0.3 ± 0.9 SDS
Observational data: associations, not effects.
Further findings
First-year response, prepubertal patients · first year of treatment
- Height increase
- 0.8 ± 0.4 SDS
- Height velocity increase
- 4.0 ± 2.1 cm/year
- PAH increase
- 0.6 ± 0.7 SDS
Response vs KIGS prediction models
- Better than expected for ISS; similar to idiopathic isolated GHD
Original publication
Growth hormone treatment adjusted for growth hormone sensitivity in idiopathic short stature. Eur J Endocrinol. Published 7 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →